Endo Int'l (ENDP) Tops Q1 EPS by 4c, Guides FY Well Below Consensus

RBC Capital Downgrades Endo International plc (ENDP) to Sector Perform

RBC Capital downgraded Endo International plc (NASDAQ: ENDP) from Outperform to Sector Perform with a price target of $26.00 (from $45.00).

Analyst Randall Stanicky commented, "We had held on to our Outperform rating despite near-term generic concerns on the view that valuation could... More

Guggenheim Cuts Price Target as Endo Int'l (ENDP) Cuts EPS Guidance

Guggenheim maintained a Buy rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $35.00 (from $65.00), following the company's 1Q earnings report. ENDP reported an adjusted EPS of $1.08, $0.03 higher than consensus estimates. The company lowered its '16 EPS guidance from $5.85-6.20 to $4.50-4.80 midpoint... More

Piper Jaffray Downgrades Endo International plc (ENDP) to Neutral

Piper Jaffray downgraded Endo International plc (NASDAQ: ENDP) from Overweight to Neutral with a price target of $25.00 (from $79.00).

Analyst David Amsellem commented, "Endo significantly lowered its 2016 guidance ranges in the wake of significant pressure on its generics segment (namely Qualitest) and opioid products in... More

Mizuho Securities Downgrades Endo International plc (ENDP) to Underperform; Stock is 'Toxic'

Mizuho Securities downgraded Endo International plc (NASDAQ: ENDP) from Neutral to Underperform with a price target of $13.00 (from $42.00).

Analyst Irina Koffler commented, "ENDP's earnings call was about as bad as it gets. Weak longer term outlook, drastically lowered guidance, and pushed out de-levering targets (4.6x leverage) are the key reasons we view the stock as toxic, and downgrade to Underperform from Neutral."

On the quarter, she weighed in: "Endo reported 1Q:16... More

Leerink Partners Downgrades Endo International plc (ENDP) to Market Perform

Leerink Partners downgraded Endo International plc (NASDAQ: ENDP) from Outperform to Market Perform with a price target of $23.00.

Analyst Jason Gerberry commented, "Based on a combination of intensifying competitive pressure to ENDPs historically high margin US generic business and underwhelming acquired brand... More